Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Vomiting 1Neoplasms, Germ Cell and Embryonal 1Nausea 1Glioma 1

Interventions

Dexamethasone 38Aprepitant 31Ondansetron 27Palonosetron 25Granisetron 16Calcium Dobesilate 15Olanzapine 12Therapeutics 8dexamethasone acetate 7Cyclophosphamide 7fosaprepitant 6casopitant 6Doxorubicin 6Radiotherapy 5netupitant 4dolasetron 4dexamethasone 21-phosphate 4Vincristine 4Tropisetron 4Metoclopramide 4Acupressure 4Yoga 3Psychiatric Rehabilitation 3Prochlorperazine 3Lorazepam 3Electroacupuncture 3Dronabinol 3Cisplatin 3Analgesia 3peppermint oil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Nausea × rolapitant × Clear all
NCT02991456 2023-07-11

Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide

Duke University

Phase 2 Completed
48 enrolled 25 charts
CNS

Glioma, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡